| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3066 | 2019 |
| Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16, 2017 | 1702 | 2017 |
| Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018 | 993 | 2018 |
| Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Nature 551 (7681), 512-516, 2017 | 983 | 2017 |
| ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a … C Luchini, F Bibeau, MJL Ligtenberg, N Singh, A Nottegar, T Bosse, ... Annals of Oncology 30 (8), 1232-1243, 2019 | 774 | 2019 |
| Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a … B O'Sullivan, SH Huang, J Su, AS Garden, EM Sturgis, K Dahlstrom, ... The Lancet Oncology 17 (4), 440-451, 2016 | 756 | 2016 |
| The head and neck cancer immune landscape and its immunotherapeutic implications R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel, MG Dalin, N Riaz, ... JCI insight 1 (17), 2016 | 673 | 2016 |
| A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520, 2017 | 591 | 2017 |
| Mitochondrial DNA copy number variation across human cancers E Reznik, ML Miller, Y Şenbabaoğlu, N Riaz, J Sarungbam, SK Tickoo, ... elife 5, e10769, 2016 | 450 | 2016 |
| Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ... Science 364 (6439), 485-491, 2019 | 439 | 2019 |
| Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy G Goh, T Walradt, V Markarov, A Blom, N Riaz, R Doumani, K Stafstrom, ... Oncotarget 7 (3), 3403, 2016 | 372 | 2016 |
| Immunogenic neoantigens derived from gene fusions stimulate T cell responses W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ... Nature medicine 25 (5), 767-775, 2019 | 306 | 2019 |
| Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival LGT Morris, N Riaz, A Desrichard, Y Şenbabaoğlu, AA Hakimi, V Makarov, ... Oncotarget 7 (9), 10051, 2016 | 289 | 2016 |
| PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer BH Lok, EE Gardner, VE Schneeberger, A Ni, P Desmeules, N Rekhtman, ... Clinical Cancer Research 23 (2), 523-535, 2017 | 288 | 2017 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30, 2021 | 271 | 2021 |
| Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ... Nature communications 12 (1), 729, 2021 | 239 | 2021 |
| Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes I Ganly, V Makarov, S Deraje, YY Dong, E Reznik, V Seshan, ... Cancer cell 34 (2), 256-270. e5, 2018 | 235 | 2018 |
| Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy D Chowell, C Krishna, F Pierini, V Makarov, NA Rizvi, F Kuo, LGT Morris, ... Nature medicine 25 (11), 1715-1720, 2019 | 229 | 2019 |
| Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy YP Chen, YQ Wang, JW Lv, YQ Li, MLK Chua, QT Le, N Lee, AD Colevas, ... Annals of Oncology 30 (1), 68-75, 2019 | 223 | 2019 |
| The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ... JAMA oncology 3 (2), 244-255, 2017 | 215 | 2017 |
